NO20012424L - Stabilisering av makrolider - Google Patents

Stabilisering av makrolider

Info

Publication number: NO20012424L
Authority: NO; Norway
Prior art keywords: macrolides; stabilization
Prior art date: 1998-12-07

Application number

NO20012424A

Other languages

English (en)

Other versions

NO20012424D0 (no

NO332698B1 (no

Inventor

Francois Navarro

Samuel Petit

Guy Stone

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-07

Filing date

2001-05-16

Publication date

2001-05-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012424(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-16 Application filed by Novartis Ag filed Critical Novartis Ag

2001-05-16 Publication of NO20012424D0 publication Critical patent/NO20012424D0/no

2001-05-16 Publication of NO20012424L publication Critical patent/NO20012424L/no

2012-12-10 Publication of NO332698B1 publication Critical patent/NO332698B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

NO20012424A 1998-12-07 2001-05-16 Fremgangsmate for stabilisering av rapamycinderivat NO332698B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9826882.4A GB9826882D0 (en)	1998-12-07	1998-12-07	Organic compounds
GBGB9904934.8A GB9904934D0 (en)	1998-12-07	1999-03-04	Organic compounds
PCT/EP1999/009521 WO2000033878A2 (en)	1998-12-07	1999-12-06	Stabilization of macrolides

Publications (3)

Publication Number	Publication Date
NO20012424D0 NO20012424D0 (no)	2001-05-16
NO20012424L true NO20012424L (no)	2001-05-16
NO332698B1 NO332698B1 (no)	2012-12-10

Family

ID=26314797

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20012424A NO332698B1 (no)	1998-12-07	2001-05-16	Fremgangsmate for stabilisering av rapamycinderivat
NO20121113A NO334612B1 (no)	1998-12-07	2012-10-01	Stabilisering av makrolider

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20121113A NO334612B1 (no)	1998-12-07	2012-10-01	Stabilisering av makrolider

Country Status (38)

Country	Link
US (5)	US6605613B2 (no)
EP (4)	EP1743657A3 (no)
JP (3)	JP3805625B2 (no)
KR (2)	KR20060096477A (no)
CN (2)	CN1261163C (no)
AR (3)	AR026102A1 (no)
AT (1)	ATE365051T1 (no)
AU (1)	AU759219B2 (no)
BE (1)	BE1012869A3 (no)
BR (1)	BR9915986A (no)
CA (3)	CA2651609A1 (no)
CO (1)	CO4980847A1 (no)
CY (1)	CY1106870T1 (no)
CZ (2)	CZ303006B6 (no)
DE (1)	DE69936352T3 (no)
DK (1)	DK1137439T4 (no)
ES (1)	ES2288033T5 (no)
FR (1)	FR2786771B1 (no)
GB (2)	GB9826882D0 (no)
HK (1)	HK1038889B (no)
HU (2)	HU228939B1 (no)
ID (1)	ID29250A (no)
IL (1)	IL143092A0 (no)
IT (1)	IT1319701B1 (no)
MY (2)	MY120594A (no)
NO (2)	NO332698B1 (no)
NZ (2)	NZ511936A (no)
PE (1)	PE20001333A1 (no)
PL (2)	PL208854B1 (no)
PT (1)	PT1137439E (no)
RU (1)	RU2243769C2 (no)
SG (1)	SG151072A1 (no)
SI (1)	SI1137439T2 (no)
SK (2)	SK286688B6 (no)
TR (2)	TR200101416T2 (no)
TW (2)	TWI270550B (no)
WO (1)	WO2000033878A2 (no)
ZA (1)	ZA200104360B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en)	2002-02-13	2008-11-18	Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Method for extracting a macrolide from biomatter
CA2475383C (en)	2002-02-13	2009-12-22	Biogal Gyogyszergyar Rt.	Method for extracting a macrolide from biomatter
KR101131794B1 (ko)	2002-07-30	2012-03-30	와이어쓰 엘엘씨	Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
KR20050114262A (ko) *	2003-03-31	2005-12-05	테바 기오기스제르갸르 레스즈베니타르사사그	마크로라이드의 결정화 및 정제
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
WO2005010015A1 (en)	2003-07-24	2005-02-03	Teva Gyogyszergyar Reszvenytarsasag	Method of purifying macrolides
CA2539324A1 (en)	2003-09-18	2005-03-31	Macusight, Inc.	Transscleral delivery
US9114198B2 (en) *	2003-11-19	2015-08-25	Advanced Cardiovascular Systems, Inc.	Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
JP2007520262A (ja) *	2003-12-10	2007-07-26	アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド	経皮または局所薬物輸送に伴う副作用の処置方法
US8551512B2 (en) *	2004-03-22	2013-10-08	Advanced Cardiovascular Systems, Inc.	Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2006039237A1 (en) *	2004-09-29	2006-04-13	Cordis Corporation	Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
BRPI0607606B1 (pt)	2005-02-09	2021-06-22	Santen Pharmaceutical, Co., Ltd.	Formulação líquida
AR058283A1 (es) *	2005-12-07	2008-01-30	Wyeth Corp	Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7700614B2 (en) *	2005-12-14	2010-04-20	Abbott Laboratories	One pot synthesis of tetrazole derivatives of rapamycin
JP2009520818A (ja) *	2005-12-20	2009-05-28	ワイス	薬物物質不純物の制御によるｃｃｉ−７７９製剤安定性の制御
CN101605529B (zh) *	2006-02-09	2013-03-13	参天制药株式会社	稳定制剂及它们的制备和使用方法
BRPI0709016A2 (pt)	2006-03-23	2011-06-21	Macusight Inc	formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
AU2011260016B2 (en)	2010-06-02	2013-08-22	Fresenius Kabi Oncology Ltd.	Stable pharmaceutical compositions of Rapamycin esters
WO2011156025A1 (en) *	2010-06-07	2011-12-15	Telik, Inc.	Crystalline Ezatiostat Hydrochloride Ansolvate
US9321782B2 (en) *	2010-08-04	2016-04-26	Meril Life Sciences Pvt. Ltd.	Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
WO2012066502A1 (en)	2010-11-19	2012-05-24	Biocon Limited	Processes for preparation of everolimus and intermediates thereof
WO2012170384A1 (en)	2011-06-06	2012-12-13	Chevron Phillips Chemical Company Lp	Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) *	2011-08-11	2013-02-14	Dong-A Pharm. Co., Ltd.	Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en)	2013-03-07	2017-04-04	Abbott Cardiovascular Systems Inc.	Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (no)	2013-07-31	2015-06-26	Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) *	2013-12-24	2018-01-30	正大天晴药业集团股份有限公司	一种稳定的依维莫司片剂
CN104892632B (zh) *	2015-06-03	2017-12-26	道中道（菏泽）制药有限公司	一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en)	2015-07-28	2019-03-20	Nippon Kayaku Kabushiki Kaisha	PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
US20190015513A1 (en) *	2015-08-28	2019-01-17	Nippon Kayaku Kabushiki Kaisha	Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017047618A1 (ja) *	2015-09-18	2017-03-23	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en)	2016-01-29	2017-08-03	Xellia Phamaceuticals Aps	Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja)	2016-05-27	2021-04-07	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) *	2018-01-12	2019-12-04	주식회사 종근당	에베로리무스를 포함하는 안정화된 약제학적 제제
EP4126882A1 (en) *	2020-03-27	2023-02-08	Boston Scientific Scimed Inc.	Methods for crystallization of drugs
JP2023028473A (ja) *	2021-08-19	2023-03-03	日本マイクロバイオファーマ株式会社	エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3996355A (en)	1975-01-02	1976-12-07	American Home Products Corporation	Permanent suspension pharmaceutical dosage form
US4049128A (en)	1976-11-18	1977-09-20	Westinghouse Air Brake Company	Control system for automatic railway car coupler
AU543727B2 (en) *	1980-06-02	1985-05-02	Ayerst Mckenna & Harrison Inc.	Injectable composition of rapamycin
GB8803836D0 (en)	1988-02-18	1988-03-16	Glaxo Group Ltd	Compositions
CA1338150C (en) †	1988-02-18	1996-03-12	Edward George Howard, Jr.	Ceramic/distillable binder compositions
KR0159766B1 (ko) *	1989-10-16	1998-12-01	후지사와 토모키치로	양모제 조성물
JPH04230389A (ja) *	1990-07-16	1992-08-19	American Home Prod Corp	ラパマイシン誘導体
FI97472C (fi) *	1991-05-07	1996-12-27	American Home Prod	Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5302584A (en) *	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
EP1266900A1 (en)	1992-10-13	2002-12-18	Wyeth	Carbamates of rapamycin
RU2181054C2 (ru) *	1994-11-02	2002-04-10	Новартис Аг	Микроэмульсионный предконцентрат
ATE228135T1 (de) *	1995-06-09	2002-12-15	Novartis Erfind Verwalt Gmbh	Rapamycinderivate
FR2736550B1 (fr) *	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
EP1208847B8 (en) *	1996-07-30	2007-02-14	Novartis AG	Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6362264B1 (en) *	1996-12-20	2002-03-26	Ck Witco Corporation	Stabilizer for food contact and medical grade PVC
JP2001511780A (ja)	1997-02-04	2001-08-14	アボツト・ラボラトリーズ	鎮痛性非経口リポソーム配合物

1998
- 1998-12-07 GB GBGB9826882.4A patent/GB9826882D0/en not_active Ceased
1999
- 1999-03-04 GB GBGB9904934.8A patent/GB9904934D0/en not_active Ceased
- 1999-11-29 CO CO99074905A patent/CO4980847A1/es unknown
- 1999-12-02 IT IT1999MI002520A patent/IT1319701B1/it active
- 1999-12-03 FR FR9915256A patent/FR2786771B1/fr not_active Expired - Lifetime
- 1999-12-03 PE PE1999001209A patent/PE20001333A1/es not_active IP Right Cessation
- 1999-12-03 AR ARP990106171A patent/AR026102A1/es active IP Right Grant
- 1999-12-04 TW TW094104943A patent/TWI270550B/zh not_active IP Right Cessation
- 1999-12-04 TW TW088121250A patent/TWI248938B/zh not_active IP Right Cessation
- 1999-12-06 JP JP2000586368A patent/JP3805625B2/ja not_active Expired - Lifetime
- 1999-12-06 AT AT99959381T patent/ATE365051T1/de active
- 1999-12-06 DE DE69936352T patent/DE69936352T3/de not_active Expired - Lifetime
- 1999-12-06 EP EP06122628A patent/EP1743657A3/en not_active Ceased
- 1999-12-06 SG SG200302502-0A patent/SG151072A1/en unknown
- 1999-12-06 HU HU0104489A patent/HU228939B1/hu unknown
- 1999-12-06 CA CA002651609A patent/CA2651609A1/en not_active Abandoned
- 1999-12-06 EP EP10179096A patent/EP2279751A3/en not_active Withdrawn
- 1999-12-06 SK SK766-2001A patent/SK286688B6/sk not_active IP Right Cessation
- 1999-12-06 CA CA2732620A patent/CA2732620C/en not_active Expired - Lifetime
- 1999-12-06 EP EP99959381A patent/EP1137439B2/en not_active Expired - Lifetime
- 1999-12-06 NZ NZ511936A patent/NZ511936A/en not_active IP Right Cessation
- 1999-12-06 CA CA2351580A patent/CA2351580C/en not_active Expired - Lifetime
- 1999-12-06 KR KR1020067017352A patent/KR20060096477A/ko not_active Ceased
- 1999-12-06 TR TR2001/01416T patent/TR200101416T2/xx unknown
- 1999-12-06 IL IL14309299A patent/IL143092A0/xx not_active IP Right Cessation
- 1999-12-06 HK HK02100663.4A patent/HK1038889B/en not_active IP Right Cessation
- 1999-12-06 CN CNB998141240A patent/CN1261163C/zh not_active Expired - Lifetime
- 1999-12-06 RU RU2001118266/15A patent/RU2243769C2/ru active
- 1999-12-06 SK SK5032-2008A patent/SK287325B6/sk not_active IP Right Cessation
- 1999-12-06 PL PL380082A patent/PL208854B1/pl unknown
- 1999-12-06 KR KR1020017007009A patent/KR100695834B1/ko not_active Expired - Lifetime
- 1999-12-06 PL PL348333A patent/PL196627B1/pl unknown
- 1999-12-06 WO PCT/EP1999/009521 patent/WO2000033878A2/en not_active Ceased
- 1999-12-06 CZ CZ20012001A patent/CZ303006B6/cs not_active IP Right Cessation
- 1999-12-06 TR TR2002/01428T patent/TR200201428T2/xx unknown
- 1999-12-06 SI SI9930985T patent/SI1137439T2/sl unknown
- 1999-12-06 CZ CZ20050170A patent/CZ302210B6/cs not_active IP Right Cessation
- 1999-12-06 ID IDW00200101156A patent/ID29250A/id unknown
- 1999-12-06 HU HU1300289A patent/HU230174B1/hu unknown
- 1999-12-06 ES ES99959381T patent/ES2288033T5/es not_active Expired - Lifetime
- 1999-12-06 BR BR9915986-4A patent/BR9915986A/pt not_active Application Discontinuation
- 1999-12-06 DK DK99959381.7T patent/DK1137439T4/da active
- 1999-12-06 AU AU16573/00A patent/AU759219B2/en not_active Expired
- 1999-12-06 CN CN2006100798040A patent/CN1876657B/zh not_active Expired - Lifetime
- 1999-12-06 PT PT99959381T patent/PT1137439E/pt unknown
- 1999-12-06 EP EP10179099A patent/EP2269651A3/en not_active Withdrawn
- 1999-12-07 MY MYPI99005309A patent/MY120594A/en unknown
- 1999-12-07 MY MYPI20043386A patent/MY127579A/en unknown
- 1999-12-07 BE BE9900799A patent/BE1012869A3/fr not_active IP Right Cessation
2001
- 2001-05-16 NO NO20012424A patent/NO332698B1/no not_active IP Right Cessation
- 2001-05-28 ZA ZA200104360A patent/ZA200104360B/en unknown
- 2001-05-29 US US09/866,977 patent/US6605613B2/en not_active Expired - Lifetime
2003
- 2003-03-21 US US10/393,795 patent/US6852729B2/en not_active Expired - Lifetime
- 2003-08-25 NZ NZ527781A patent/NZ527781A/en not_active IP Right Cessation
2004
- 2004-12-23 US US11/020,860 patent/US7297703B2/en not_active Expired - Lifetime
2005
- 2005-02-28 AR ARP050100744A patent/AR048073A2/es active IP Right Grant
- 2005-04-01 JP JP2005106512A patent/JP5043308B2/ja not_active Expired - Lifetime
- 2005-12-28 JP JP2005378514A patent/JP5165199B2/ja not_active Expired - Lifetime
2006
- 2006-05-04 AR ARP060101807A patent/AR054444A2/es active IP Right Grant
2007
- 2007-09-14 CY CY20071101192T patent/CY1106870T1/el unknown
- 2007-10-11 US US11/973,927 patent/US7572804B2/en not_active Expired - Fee Related
2009
- 2009-07-06 US US12/497,728 patent/US7741338B2/en not_active Expired - Fee Related
2012
- 2012-10-01 NO NO20121113A patent/NO334612B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
US6852729B2 (en)	2005-02-08
TWI270550B (en)	2007-01-11
WO2000033878A3 (en)	2000-11-02
ES2288033T3 (es)	2007-12-16
KR20010101128A (ko)	2001-11-14
HK1038889B (en)	2008-01-25
CN1374872A (zh)	2002-10-16
US7741338B2 (en)	2010-06-22
DE69936352D1 (de)	2007-08-02
CA2651609A1 (en)	2000-06-15
US7572804B2 (en)	2009-08-11
US7297703B2 (en)	2007-11-20
SK287325B6 (sk)	2010-07-07
TWI248938B (en)	2006-02-11
JP5165199B2 (ja)	2013-03-21
EP1743657A2 (en)	2007-01-17
EP1137439B1 (en)	2007-06-20
SI1137439T2 (sl)	2012-05-31
PT1137439E (pt)	2007-09-25
KR20060096477A (ko)	2006-09-11
AR048073A2 (es)	2006-03-29
HU230174B1 (hu)	2015-09-28
EP1137439B2 (en)	2011-11-23
JP3805625B2 (ja)	2006-08-02
AR026102A1 (es)	2003-01-29
CA2351580C (en)	2012-03-20
JP2006111637A (ja)	2006-04-27
WO2000033878A2 (en)	2000-06-15
EP2269651A2 (en)	2011-01-05
JP2005200429A (ja)	2005-07-28
MY120594A (en)	2005-11-30
EP1743657A3 (en)	2007-03-28
US20050107418A1 (en)	2005-05-19
HUP0104489A2 (hu)	2002-03-28
US20020032213A1 (en)	2002-03-14
NZ527781A (en)	2004-11-26
FR2786771B1 (fr)	2002-12-27
NO20012424D0 (no)	2001-05-16
IT1319701B1 (it)	2003-10-27
CN1261163C (zh)	2006-06-28
ATE365051T1 (de)	2007-07-15
SK286688B6 (sk)	2009-03-05
CA2732620A1 (en)	2000-06-15
AU1657300A (en)	2000-06-26
DE69936352T2 (de)	2008-02-14
US20090270441A1 (en)	2009-10-29
ID29250A (id)	2001-08-16
GB9826882D0 (en)	1999-01-27
HUP0104489A3 (en)	2004-05-28
IL143092A0 (en)	2002-04-21
CN1876657B (zh)	2013-01-09
DE69936352T3 (de)	2012-05-03
HK1038889A1 (en)	2002-04-04
DK1137439T4 (da)	2012-03-19
PL208854B1 (pl)	2011-06-30
NO20121113L (no)	2001-05-16
PE20001333A1 (es)	2000-12-12
ITMI992520A1 (it)	2001-06-02
AR054444A2 (es)	2007-06-27
CY1106870T1 (el)	2012-09-26
DK1137439T3 (da)	2007-09-10
HU228939B1 (en)	2013-07-29
EP1137439A2 (en)	2001-10-04
JP5043308B2 (ja)	2012-10-10
CZ20012001A3 (cs)	2001-09-12
NO332698B1 (no)	2012-12-10
US6605613B2 (en)	2003-08-12
NO334612B1 (no)	2014-04-22
CZ302210B6 (cs)	2010-12-22
PL348333A1 (en)	2002-05-20
PL196627B1 (pl)	2008-01-31
FR2786771A1 (fr)	2000-06-09
EP2279751A2 (en)	2011-02-02
ES2288033T5 (es)	2012-04-10
EP2269651A3 (en)	2011-03-09
US20080161334A1 (en)	2008-07-03
BR9915986A (pt)	2001-09-04
SI1137439T1 (sl)	2008-06-30
NZ511936A (en)	2003-10-31
TR200101416T2 (tr)	2002-01-21
SG151072A1 (en)	2009-06-29
KR100695834B1 (ko)	2007-03-19
MY127579A (en)	2006-12-29
CZ303006B6 (cs)	2012-02-22
SK7662001A3 (en)	2001-12-03
US20030191148A1 (en)	2003-10-09
CN1876657A (zh)	2006-12-13
GB9904934D0 (en)	1999-04-28
RU2243769C2 (ru)	2005-01-10
CA2732620C (en)	2013-08-06
BE1012869A3 (fr)	2001-04-03
CO4980847A1 (es)	2000-11-27
ITMI992520A0 (it)	1999-12-02
TR200201428T2 (tr)	2002-12-23
CA2351580A1 (en)	2000-06-15
JP2002531527A (ja)	2002-09-24
TW200540179A (en)	2005-12-16
AU759219B2 (en)	2003-04-10
EP2279751A3 (en)	2011-02-16
ZA200104360B (en)	2002-01-16

Publication	Publication Date	Title
NO20012424L (no)	2001-05-16	Stabilisering av makrolider
ID29021A (id)	2001-07-26	Komposisi galantamina pelepasan terkontrol
PT945132E (pt)	2004-08-31	Composicao de ibuprofeno
ID27092A (id)	2001-03-01	Pembuatan ftalat anhidrida
DE69908713D1 (de)	2003-07-17	Selektive Helligkeitserweiterung
FI980783A0 (fi)	1998-04-03	Foerfarande foer utformning av en signaleringsfoerbindelse
DE69932169D1 (de)	2006-08-10	Formular
NO20010899L (no)	2001-04-24	Forbedring av ugunstige apomorfin-effekter
EE200100135A (et)	2002-06-17	EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
NO994790L (no)	2000-04-03	Estimering av permabilitet
FI980150A0 (fi)	1998-01-23	Foerfarande foer oeverfoering av bildinformation
DE69906921D1 (de)	2003-05-22	Erweiterung des Farbtonumfangs
FI980222A0 (fi)	1998-01-30	Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
FI980527A0 (fi)	1998-03-09	Anordning foer svaengning av en lastlucka pao ett fraktfartyg
FI980268A0 (fi)	1998-02-06	Foerfarande foer framstaellning av cykliska monomerer
NO20004109L (no)	2002-02-18	Stabilisering av formasjoner
FI980095A0 (fi)	1998-01-19	Foerfarande foer byggande av fartyg
DE69921383D1 (de)	2004-12-02	Regelung kritischer Abmessungen
PT1232141E (pt)	2004-12-31	Eteres de o-desmetil-venlafaxina
FI982552A0 (fi)	1998-11-25	Stabilointimenetelmä
ID23032A (id)	2000-01-06	Komposisi insektisida
AU2003200370A1 (en)	2003-04-17	Stabilization of macrolides
FI980146A0 (fi)	1998-01-23	Foerfarande foer roentgenavbildning av huvud- och halsomraodet
FI980470A0 (fi)	1998-03-02	Anvaendning av kyl- och bakvattnen i vattenhydraulikapplikationer i pappers- och kartongmaskiner
FI980117A0 (fi)	1998-01-20	Foerfarande foer framstaellning av en plastprodukt

Legal Events

Date	Code	Title	Description
2020-01-13	MK1K	Patent expired